Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (10): 983-986.DOI: 10.3969/j.issn.1673-8640.2023.10.015
Previous Articles Next Articles
Received:2020-06-27
Revised:2023-06-10
Online:2023-10-30
Published:2023-12-18
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.10.015
| 试剂 | 肝素钠浓度 | ||||||
|---|---|---|---|---|---|---|---|
| 0.000 U/mL | 0.104 U/mL | 0.178 U/mL | 0.250 U/mL | 0.313 U/mL | 0.417 U/mL | 0.625 U/mL | |
| HS试剂 | 21.1±3.8 | 22.3±4.7 | 25.4±6.9 | 39.6±9.8 | 49.6±14.8 | 62.4±18.9 | 83.7±24.6 |
| DAACR试剂 | 19.2±4.3 | 24.5±5.4 | 28.9±7.3 | 43.8±11.4 | 63.8±18.5 | 91.2±25.6 | 132.45±38.7 |
| 试剂 | 肝素钠浓度 | ||||||
|---|---|---|---|---|---|---|---|
| 0.000 U/mL | 0.104 U/mL | 0.178 U/mL | 0.250 U/mL | 0.313 U/mL | 0.417 U/mL | 0.625 U/mL | |
| HS试剂 | 21.1±3.8 | 22.3±4.7 | 25.4±6.9 | 39.6±9.8 | 49.6±14.8 | 62.4±18.9 | 83.7±24.6 |
| DAACR试剂 | 19.2±4.3 | 24.5±5.4 | 28.9±7.3 | 43.8±11.4 | 63.8±18.5 | 91.2±25.6 | 132.45±38.7 |
| 试剂 | 凝血因子Ⅷ | 凝血因子Ⅸ | 凝血因子Ⅺ | 凝血因子Ⅻ |
|---|---|---|---|---|
| HS试剂 | 52.1 | 32.4 | 46.3 | 49.8 |
| DAACR试剂 | 45.0 | 38.6 | 54.2 | 42.8 |
| 试剂 | 凝血因子Ⅷ | 凝血因子Ⅸ | 凝血因子Ⅺ | 凝血因子Ⅻ |
|---|---|---|---|---|
| HS试剂 | 52.1 | 32.4 | 46.3 | 49.8 |
| DAACR试剂 | 45.0 | 38.6 | 54.2 | 42.8 |
| 试剂 | 抗Ⅹa活性 | ||||||
|---|---|---|---|---|---|---|---|
| 0.34 IU/mL | 0.46 IU/mL | 0.61 IU/mL | 0.53 IU/mL | 0.42 IU/mL | 0.37 IU/mL | 0.26 IU/mL | |
| DAACR试剂检测 | 46.3 | 56.7 | 67.4 | 57.4 | 55.3 | 52.6 | 38.2 |
| HS试剂检测 | 52.1 | 61.4 | 75.4 | 67.6 | 60.5 | 57.3 | 44.3 |
| 试剂 | 抗Ⅹa活性 | ||||||
|---|---|---|---|---|---|---|---|
| 0.34 IU/mL | 0.46 IU/mL | 0.61 IU/mL | 0.53 IU/mL | 0.42 IU/mL | 0.37 IU/mL | 0.26 IU/mL | |
| DAACR试剂检测 | 46.3 | 56.7 | 67.4 | 57.4 | 55.3 | 52.6 | 38.2 |
| HS试剂检测 | 52.1 | 61.4 | 75.4 | 67.6 | 60.5 | 57.3 | 44.3 |
| 试剂 | 抗Ⅹa活性 | ||||||
|---|---|---|---|---|---|---|---|
| 0.38 IU/mL | 0.57 IU/mL | 0.48 IU/mL | 0.43 IU/mL | 0.41 IU/mL | 0.33 IU/mL | 0.38 IU/mL | |
| DAACR试剂检测 | 50.2 | 54.6 | 61.1 | 58.3 | 56.4 | 48.2 | 52.4 |
| HS试剂检测 | 55.7 | 77.2 | 71.5 | 64.8 | 62.8 | 56.5 | 57.2 |
| 试剂 | 抗Ⅹa活性 | ||||||
|---|---|---|---|---|---|---|---|
| 0.38 IU/mL | 0.57 IU/mL | 0.48 IU/mL | 0.43 IU/mL | 0.41 IU/mL | 0.33 IU/mL | 0.38 IU/mL | |
| DAACR试剂检测 | 50.2 | 54.6 | 61.1 | 58.3 | 56.4 | 48.2 | 52.4 |
| HS试剂检测 | 55.7 | 77.2 | 71.5 | 64.8 | 62.8 | 56.5 | 57.2 |
| [1] | 刘秋月. 血凝试验检测结果质量的影响因素及改善对策分析[J]. 实用医技杂志, 2017, 24(6):641-643. |
| [2] | Clinical and Laboratory Standards Institute. One-stage prothrombin time(PT) test and activated partial thromboplastin time(APTT) test[S]. H47-A2,CLSI, 2008. |
| [3] | DOUGLAS A, TRIPLETT. Laboratory evaluation of coagulation[M]. Chicago: Amer Society of Clinical Press, 1982. |
| [4] | ELAINE M K, CATHERINE N O, JEANINE M W. Rodak's hematology:clinical principles and applications[M]. 5th edition. Ashland: Saunders, 2015. |
| [5] |
SALANI R, BRISTOW R E. Surgical management of epithelial ovarian cancer[J]. Clin Obstet Gynecol, 2012, 55(1):75-95.
DOI PMID |
| [6] | 王威, 袁莉, 何晓璇, 等. 试剂因子敏感性差异导致APTT室间质量评价失控分析[J]. 检验医学, 2018, 33(12):1136-1139. |
| [7] | 中华医学会风湿病学分会. 抗磷脂综合征诊断和治疗指南[J]. 中华风湿病学杂志, 2011, 15(6):407-410. |
| [8] |
FANGTHAM M, PETRI M. 2013 Update:Hopkins lupus cohort[J]. Curr Rheumatol Rep, 2013, 15(9):360.
DOI URL |
| [9] |
PENGO V, TRIPODI A, REBER G, et al. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the International Society on Thrombosis and Haemostasis[J]. J Thromb Haemost, 2009, 7(10):1737-1740.
DOI URL |
| [10] | 付璐, 李洁, 董丽梅, 等. 3种APTT试剂对LA的初筛价值[J]. 检验医学, 2019, 34(9):841-843. |
| [11] |
RASMUSSEN K L, PHILIPS M, TRIPODI A, et al. Unexpected,isolated activated partial thromboplastin time prolongation:a practical mini-review[J]. Eur J Haematol, 2020, 104(6):519-525.
DOI URL |
| [12] |
RATANO D, ALBERIO L, DELODDER F, et al. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin[J]. Thromb Res, 2019, 175:53-58.
DOI PMID |
| [13] |
HIRSH J, RASCHKE R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy[J]. Chest. 2004, 126(3 Suppl):188S-203S.
DOI PMID |
| [14] |
EIKELBOOM J W, HIRSH J. Monitoring unfractionated heparin with the aPTT:time for a fresh look[J]. Thromb Haemost, 2006, 96(5):547-552.
DOI URL |
| [1] | DENG Chenxia, MEI Yanping, ZHANG Xia, HUANG Baoshan, TIAN Dan, CAO Mengting, HU Yongqi, LIN Yongping, TIAN Lijun. Depolymerization effect of optical platelet count on reversible platelet aggregation after blood collection [J]. Laboratory Medicine, 2023, 38(11): 1087-1090. |
| [2] | LU Tingyan, GU Danfeng, WANG Yahong, GE Yafang, YANG Haiou. Evaluation of vaginal secretion routine determination modes and review criteria analysis [J]. Laboratory Medicine, 2023, 38(11): 1091-1097. |
| [3] | . [J]. Laboratory Medicine, 2023, 38(11): 1098-1100. |
| [4] | . [J]. Laboratory Medicine, 2023, 38(9): 901-904. |
| [5] | . [J]. Laboratory Medicine, 2023, 38(9): 905-908. |
| [6] | CHENG Xu, YANG Cunqing, PANG Bo, GU Chun, HOU Xueyun, FEI Jiaxin, WU Min, LI Jun, LIU Guijian. Number and activity of peripheral blood eosinophils in obese people [J]. Laboratory Medicine, 2023, 38(9): 855-859. |
| [7] | LEI Jing, MAN Qiuhong, ZHAO Renjia, ZHANG Tiejun, JIANG Yanfeng, XU Kelin, SUO Chen, CHEN Xingdong. Elevated red blood cell distribution width increasing the risk of heart failure：a cohort study based on the UK Biobank [J]. Laboratory Medicine, 2023, 38(9): 860-864. |
| [8] | DUAN Lili, JIANG Chang, ZHOU Dongmei. Role of PLR in ankylosing spondylitis patients with positive antinuclear antibody [J]. Laboratory Medicine, 2023, 38(7): 669-674. |
| [9] | XIA Yanyan, XIA Yongquan, SONG Guanghao, XIA Mao. Role of coagulation-related monitoring indicators in the course of rivaroxaban anticoagulation for acute venous thromboembolism in elderly patients [J]. Laboratory Medicine, 2023, 38(5): 475-478. |
| [10] | CHEN Yi, WANG Jia, XU Zhiwei, ZHAI Yaping, XUAN Weixia. Effects of different anticoagulants on phagocytosis，activation and apoptosis of in vitro neutrophil function [J]. Laboratory Medicine, 2023, 38(5): 479-483. |
| [11] | YANG Liyuan, DAI Wanqin, WANG Xiaotong, LOU Xiaoli, WANG Yue, HOU Yanqiang. Effect of peripheral blood neutrophils on interferon-gamma release assay of Mycobacterium tuberculosis [J]. Laboratory Medicine, 2023, 38(5): 484-488. |
| [12] | . [J]. Laboratory Medicine, 2023, 38(5): 502-504. |
| [13] | . [J]. Laboratory Medicine, 2023, 38(1): 69-72. |
| [14] | XIE Yuan, YI Wanwan, SHI Qiuyuan, LÜ Zhongwei, LIU Jin. Clinical value of thromboelastography and conventional coagulation tests in evaluating coagulation status of colon cancer and colon polyps [J]. Laboratory Medicine, 2022, 37(11): 1007-1011. |
| [15] | MIAO Wenjia, GU Hao, LI Gang. Clinical application of maximum aggregation rate and thrombus maximum amplitude in children with Glanzmann thrombasthenia and Bernard-Soulier syndrome [J]. Laboratory Medicine, 2022, 37(11): 1026-1029. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
